CAR-NKT cells targeting CD70 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-NKT) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments and whose tumors are CD70-positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your cancer must be an advanced solid tumor that has continued to grow or come back after at least two prior treatments.
- Your tumor must test positive for a protein called CD70 (a special test is needed).
- You must have at least one tumor that can be measured on a scan (like CT or MRI).
- Your liver, kidney, and blood counts must be working basically normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.